<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000830</url>
  </required_header>
  <id_info>
    <org_study_id>64,185-205</org_study_id>
    <nct_id>NCT02000830</nct_id>
  </id_info>
  <brief_title>Follow up Study of Patients Having Participated in Clinical Trial 64,185-204</brief_title>
  <acronym>JASMINE_205</acronym>
  <official_title>A 48-52 Month Blinded-Outcomes Follow up Study of Patients Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-204</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfaCare Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InfaCare Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this follow up study are to evaluate the long-term effects of
      stannsoporfin (Stanate) on the health, growth, and development of patients who received a
      single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients
      in the control (placebo plus PT) group in clinical trial 64,185-204.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcomes will be based on the following variables:

      Reported AEs and SAEs Hearing assessments Developmental assessments
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reported adverse events (AEs)</measure>
    <time_frame>48-52 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hearing assessments</measure>
    <time_frame>48 - 52 month</time_frame>
    <description>Conventional audiometry will be performed by a qualified specialist. Any findings from a failed conventional audiology examination will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental assessments</measure>
    <time_frame>48 - 52 month</time_frame>
    <description>The Mullen Scales of Early Learning examination has been selected for its standardized measurement of developmental skills in multiple domains (gross motor, visual reception, fine motor, expressive language, and receptive language). Testing will be done at visits 1 and 2 by a healthcare individual trained to administer the test. The Mullen raw scores, T-scores, and age equivalents will be recorded.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Evaluate the Long-term Health Effects of Stannsoporfin on Patients From Clinical Trial 64,185-204.</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>stannsoporfin 3.0 mg/kg</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>stannsoporfin 4.5 mg/kg</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stannsoporofin</intervention_name>
    <arm_group_label>stannsoporfin 3.0 mg/kg</arm_group_label>
    <arm_group_label>stannsoporfin 4.5 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who received a single dose of trial medication in clinical trial 64,185-204.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received IMP (stannsoporfin or placebo) in clinical trial 64,185-204

          -  Parents or guardians have given written informed consent to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>52 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simmon Tulloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>InfaCare Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 9, 2016</lastchanged_date>
  <firstreceived_date>June 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stannsoporfin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
